NEKTAR THERAPEUTICS (NKTR)

US6402681083 - Common Stock

0.9078  +0.01 (+0.81%)

After market: 0.8928 -0.02 (-1.65%)

Fundamental Rating

3

NKTR gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. While NKTR seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, NKTR is valued expensive at the moment.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year NKTR has reported negative net income.
In the past year NKTR has reported a negative cash flow from operations.
In the past 5 years NKTR always reported negative net income.
NKTR had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

NKTR has a Return On Assets of -54.65%. This is in the lower half of the industry: NKTR underperforms 64.74% of its industry peers.
The Return On Equity of NKTR (-344.29%) is worse than 77.89% of its industry peers.
Industry RankSector Rank
ROA -54.65%
ROE -344.29%
ROIC N/A
ROA(3y)-56.02%
ROA(5y)-43.84%
ROE(3y)-129.42%
ROE(5y)-92.18%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

NKTR's Gross Margin of 67.80% is fine compared to the rest of the industry. NKTR outperforms 71.05% of its industry peers.
NKTR's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for NKTR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 67.8%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-10.51%
GM growth 5Y-8.59%

More info and screens

6

2. Health

2.1 Basic Checks

NKTR does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NKTR has been increased compared to 1 year ago.
Compared to 5 years ago, NKTR has more shares outstanding
There is no outstanding debt for NKTR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -16.29, we must say that NKTR is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -16.29, NKTR is doing worse than 83.16% of the companies in the same industry.
NKTR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -16.29
ROIC/WACCN/A
WACC9.82%

2.3 Liquidity

NKTR has a Current Ratio of 4.24. This indicates that NKTR is financially healthy and has no problem in meeting its short term obligations.
NKTR has a better Current ratio (4.24) than 61.58% of its industry peers.
A Quick Ratio of 4.24 indicates that NKTR has no problem at all paying its short term obligations.
NKTR has a Quick ratio of 4.24. This is in the better half of the industry: NKTR outperforms 63.68% of its industry peers.
Industry RankSector Rank
Current Ratio 4.24
Quick Ratio 4.24

More info and screens

4

3. Growth

3.1 Past

NKTR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 26.96%, which is quite impressive.
NKTR shows a small growth in Revenue. In the last year, the Revenue has grown by 5.60%.
NKTR shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -40.35% yearly.
EPS 1Y (TTM)26.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
Revenue 1Y (TTM)5.6%
Revenue growth 3Y-16.16%
Revenue growth 5Y-40.35%
Sales Q2Q%-0.08%

3.2 Future

Based on estimates for the next years, NKTR will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.67% on average per year.
The Revenue is expected to grow by 17.14% on average over the next years. This is quite good.
EPS Next Y26.35%
EPS Next 2Y11.61%
EPS Next 3Y9.67%
EPS Next 5YN/A
Revenue Next Year18.45%
Revenue Next 2Y2.45%
Revenue Next 3Y1.47%
Revenue Next 5Y17.14%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NKTR. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NKTR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.61%
EPS Next 3Y9.67%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NKTR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEKTAR THERAPEUTICS

NASDAQ:NKTR (12/24/2024, 7:28:10 PM)

After market: 0.8928 -0.02 (-1.65%)

0.9078

+0.01 (+0.81%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)N/A N/A
Inst Owners74.29%
Inst Owner Change5.5%
Ins Owners1.06%
Ins Owner Change11.18%
Market Cap167.45M
Analysts75
Price Target4.18 (360.45%)
Short Float %2.43%
Short Ratio2.37
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.04%
Min EPS beat(2)-20.38%
Max EPS beat(2)16.31%
EPS beat(4)2
Avg EPS beat(4)-0.91%
Min EPS beat(4)-20.38%
Max EPS beat(4)16.31%
EPS beat(8)4
Avg EPS beat(8)-1.06%
EPS beat(12)8
Avg EPS beat(12)5.69%
EPS beat(16)12
Avg EPS beat(16)6.57%
Revenue beat(2)2
Avg Revenue beat(2)30.32%
Min Revenue beat(2)29.38%
Max Revenue beat(2)31.25%
Revenue beat(4)4
Avg Revenue beat(4)32.15%
Min Revenue beat(4)29.38%
Max Revenue beat(4)38.28%
Revenue beat(8)6
Avg Revenue beat(8)16.99%
Revenue beat(12)7
Avg Revenue beat(12)10.68%
Revenue beat(16)8
Avg Revenue beat(16)5.33%
PT rev (1m)54.72%
PT rev (3m)215.39%
EPS NQ rev (1m)0%
EPS NQ rev (3m)25.62%
EPS NY rev (1m)7.99%
EPS NY rev (3m)8.83%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)72.1%
Revenue NY rev (1m)17.81%
Revenue NY rev (3m)28.9%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.8
P/FCF N/A
P/OCF N/A
P/B 3.43
P/tB 3.43
EV/EBITDA N/A
EPS(TTM)-0.84
EYN/A
EPS(NY)-0.79
Fwd EYN/A
FCF(TTM)-0.96
FCFYN/A
OCF(TTM)-0.96
OCFYN/A
SpS0.5
BVpS0.27
TBVpS0.27
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -54.65%
ROE -344.29%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 67.8%
FCFM N/A
ROA(3y)-56.02%
ROA(5y)-43.84%
ROE(3y)-129.42%
ROE(5y)-92.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-10.51%
GM growth 5Y-8.59%
F-Score4
Asset Turnover0.3
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 22.45%
Cap/Sales 1.37%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.24
Quick Ratio 4.24
Altman-Z -16.29
F-Score4
WACC9.82%
ROIC/WACCN/A
Cap/Depr(3y)53.77%
Cap/Depr(5y)82.39%
Cap/Sales(3y)7.29%
Cap/Sales(5y)9.92%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)26.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
EPS Next Y26.35%
EPS Next 2Y11.61%
EPS Next 3Y9.67%
EPS Next 5YN/A
Revenue 1Y (TTM)5.6%
Revenue growth 3Y-16.16%
Revenue growth 5Y-40.35%
Sales Q2Q%-0.08%
Revenue Next Year18.45%
Revenue Next 2Y2.45%
Revenue Next 3Y1.47%
Revenue Next 5Y17.14%
EBIT growth 1Y6.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year44.84%
EBIT Next 3Y10.87%
EBIT Next 5YN/A
FCF growth 1Y56.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y55.64%
OCF growth 3YN/A
OCF growth 5YN/A